Herantis Pharma's Lymfactin study advances to last patient cohort, company announces initial plans for continued development
Herantis Pharma's Lymfactin study advances to last patient cohort, company announces initial plans for continued development Herantis Pharma PlcCompany release 22 June 2017 at 9:00 am Herantis Pharma Plc's ("Herantis") clinical study with the company's investigational gene therapy product Lymfactin® for the treatment of secondary lymphedema has advanced to the last patient cohort, owing to good reported safety. After assessing safety data on all treated patients, including the first patients treated with the highest dose, the study's Data Monitoring Committee of independent experts